Cargando…

Comparative cardiovascular outcomes in type 2 diabetes patients taking dapagliflozin versus empagliflozin: a nationwide population-based cohort study

BACKGROUND: Sodium-glucose co-transporter-2 inhibitors displayed cardiovascular benefits in type 2 diabetes mellitus in previous studies; however, there were some heterogeneities regarding respective cardiovascular outcomes within the class. Furthermore, their efficacies in Asians, females, and thos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lim, Jaehyun, Choi, You-Jung, Kim, Bong Sung, Rhee, Tae-Min, Lee, Hyun-Jung, Han, Kyung-Do, Park, Jun-Bean, Na, Jin Oh, Kim, Yong-Jin, Lee, Heesun, Kim, Hyung-Kwan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373410/ https://www.ncbi.nlm.nih.gov/pubmed/37496050 http://dx.doi.org/10.1186/s12933-023-01911-7

Ejemplares similares

Impact of coronary artery revascularization on long-term outcome in hypertrophic cardiomyopathy patients: a nationwide population-based cohort study
por: Rhee, Tae-Min, et al.
Publicado: (2023)

Safety and effectiveness of anticoagulation with non-vitamin K antagonist oral anticoagulants and warfarin in patients on tuberculosis treatment
por: Lee, Hyun-Jung, et al.
Publicado: (2023)

Emergency department utilization in patients with hypertrophic cardiomyopathy: a nationwide population-based study
por: Choi, You-Jung, et al.
Publicado: (2022)

Augmented risk of ischemic stroke in hypertrophic cardiomyopathy patients without documented atrial fibrillation
por: Choi, You-Jung, et al.
Publicado: (2022)

Clinical impact of atrial fibrillation in a nationwide cohort of hypertrophic cardiomyopathy patients
por: Lee, Hyun-Jung, et al.
Publicado: (2020)

Risk of upper gastrointestinal bleeding in patients on oral anticoagulant and proton pump inhibitor co-therapy
por: Lee, Hyun-Jung, et al.
Publicado: (2021)

Characteristics of Dapagliflozin Responders: A Longitudinal, Prospective, Nationwide Dapagliflozin Surveillance Study in Korea
por: Han, Eugene, et al.
Publicado: (2018)

Sex differences in the prognosis of patients with hypertrophic cardiomyopathy
por: Kim, Minkwan, et al.
Publicado: (2021)

Pharmacokinetic and pharmacodynamic drug–drug interactions between evogliptin and empagliflozin or dapagliflozin in healthy male volunteers
por: Kim, Dasohm, et al.
Publicado: (2023)

Trends of the prevalence and incidence of hypertrophic cardiomyopathy in Korea: A nationwide population-based cohort study
por: Moon, Inki, et al.
Publicado: (2020)

Dapagliflozin versus empagliflozin in patients with chronic kidney disease
por: Alnsasra, Hilmi, et al.
Publicado: (2023)

Safety and Effectiveness of Empagliflozin in Korean Patients with Type 2 Diabetes Mellitus: Results from a Nationwide Post-Marketing Surveillance
por: Moon, Jun Sung, et al.
Publicado: (2023)

Effects of Empagliflozin on Diuretics Reduction in Outpatient Heart Failure Patients
por: Kim, Soo-Jin, et al.
Publicado: (2022)

Eligibility of Dapagliflozin and Empagliflozin in a Real-World Heart Failure Population
por: Håkansson, Erik, et al.
Publicado: (2021)

A Comparison of the Pharmacokinetics and Safety of Dapagliflozin Formate, an Ester Prodrug of Dapagliflozin, to Dapagliflozin Propanediol Monohydrate in Healthy Subjects
por: Kim, Hyun Chul, et al.
Publicado: (2023)

Dapagliflozin and Empagliflozin in Heart Failure with Reduced Ejection Fraction: A Retrospective Study
por: Hao, Zhengyang, et al.
Publicado: (2022)

Augmented risk of dementia in hypertrophic cardiomyopathy: A propensity score matching analysis using the nationwide cohort
por: Lee, Heesun, et al.
Publicado: (2022)

Renal and Glucose-Lowering Effects of Empagliflozin and Dapagliflozin in Different Chronic Kidney Disease Stages
por: Lin, Yi-Hsuan, et al.
Publicado: (2019)

Study comparing the efficacy and renal safety for patients with diabetes switching from dapagliflozin to empagliflozin
por: Yang, Ai-Yu, et al.
Publicado: (2020)

Comparison of safety and efficacy of dapagliflozin and empagliflozin in type 2 diabetes mellitus patients in India
por: Varshney, Amit, et al.
Publicado: (2023)

Comparison of mortality and cause of death between adults with and without hypertrophic cardiomyopathy
por: Kwon, Soonil, et al.
Publicado: (2022)

Effect of Empagliflozin, a Selective Sodium-Glucose Cotransporter 2 Inhibitor, on Kidney and Peripheral Nerves in Streptozotocin-Induced Diabetic Rats
por: Lee, Kyung Ae, et al.
Publicado: (2018)

Independent Impact of Diabetes on the Severity of Coronavirus Disease 2019 in 5,307 Patients in South Korea: A Nationwide Cohort Study
por: Moon, Sun Joon, et al.
Publicado: (2020)

Empagliflozin Reduces the Progression of Hepatic Fibrosis in a Mouse Model and Inhibits the Activation of Hepatic Stellate Cells via the Hippo Signalling Pathway
por: Heo, Yu-Jung, et al.
Publicado: (2022)

Risk of end-stage renal disease in patients with hypertrophic cardiomyopathy: A nationwide population-based cohort study
por: Lee, Heesun, et al.
Publicado: (2019)

Relation between Baseline Height and New Diabetes Development: A Nationwide Population-Based Study
por: Rhee, Eun-Jung, et al.
Publicado: (2019)

Dapagliflozin attenuates diabetes-induced diastolic dysfunction and cardiac fibrosis by regulating SGK1 signaling
por: Lee, Seul-Gee, et al.
Publicado: (2022)

Empagliflozin and Dulaglutide are Effective against Obesity-induced Airway Hyperresponsiveness and Fibrosis in A Murine Model
por: Park, Hye Jung, et al.
Publicado: (2019)

Comparative Efficacy of Dapagliflozin and Empagliflozin of a Fixed Dose in Heart Failure: A Network Meta-Analysis
por: Shi, Zepeng, et al.
Publicado: (2022)

Comparison of Cardiovascular Outcomes Between Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes: A Meta-Analysis
por: Memon, Rahat A, et al.
Publicado: (2022)

Comparative Safety Analysis of Empagliflozin in Type 2 Diabetes Mellitus Patients with Chronic Kidney Disease versus Normal Kidney Function: A Nationwide Cohort Study in Korea
por: Jang, Ha Young, et al.
Publicado: (2023)

Sodium/glucose Co-Transporter 2 Inhibitor, Empagliflozin, Alleviated Transient Expression of SGLT2 after Myocardial Infarction
por: Lee, Soo Yong, et al.
Publicado: (2020)

Use of dapagliflozin in patients with advanced diabetic kidney disease
por: Park, Hyun Sun, et al.
Publicado: (2018)

Butyrate attenuated fat gain through gut microbiota modulation in db/db mice following dapagliflozin treatment
por: Oh, Tae Jung, et al.
Publicado: (2019)

Protective effect of smoking cessation on subsequent myocardial infarction and ischemic stroke independent of weight gain: A nationwide cohort study
por: Cho, Jung-Hwan, et al.
Publicado: (2020)

Anti-inflammatory Effects of Empagliflozin and Gemigliptin on LPS-Stimulated Macrophage via the IKK/NF-κB, MKK7/JNK, and JAK2/STAT1 Signalling Pathways
por: Lee, Nami, et al.
Publicado: (2021)

Association between Low-Density Lipoprotein Cholesterol Level and Cardiovascular Outcomes in Korean Adults: A Nationwide Cohort Study
por: Noh, Junghyun, et al.
Publicado: (2023)

Maintenance of body weight is an important determinant for the risk of ischemic stroke: A nationwide population-based cohort study
por: Cho, Jung-Hwan, et al.
Publicado: (2019)

Quantitative effects of sodium–glucose cotransporter-2 inhibitors dapagliflozin and empagliflozin on quality of life in heart failure patients
por: Wang, Dong-Dong, et al.
Publicado: (2022)

Risk of ischemic stroke in metabolically healthy obesity: A nationwide population-based study
por: Lee, Hyun-Jung, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_p3r3fh7nk1i2uvdpmgvel93h1m